LataMed Q3 10-Q: Zero Cash, $198,329 Nine-Month Loss, Going Concern Stands
LMED sits 40% above its 52-week low of $0.026 on light trading volume (0.1× avg).
Summary
LataMed's Q3 10-Q shows zero cash, a nine-month net loss of $198,329 and a $29.8M accumulated deficit, with management repeating its going concern warning and no committed financing in place.
Key Events · Earnings and Guidance · LMED
-
Zero Cash, Going Concern Reiterated
Cash was $0 at September 30, 2026, and management states the $198,329 nine-month net loss and $29,799,115 accumulated deficit raise substantial doubt about the ability to continue as a going concern.
-
Loss Widens Year Over Year
Q3 net loss was $58,108 versus $36,302 in Q3 2025; the nine-month loss was $198,329 versus $89,939, driven by higher professional fees and interest expense.
-
Debt-Funded Operations
The company issued $117,084 of 10% promissory notes due on demand in the nine months, lifting notes payable to $389,388 from $272,304; the working capital deficit widened to $829,189 from $630,860.
-
No Committed Financing
Management says it has no firm agreements for financing and intends to pursue a private equity offering, warning that any equity raise may involve substantial dilution.
Analysis · LMED · Technology
With no revenue and no cash on the balance sheet at September 30, 2026, LataMed's nine-month net loss widened to $198,329 from $89,939 a year earlier. The accumulated deficit now stands at $29,799,115, and management repeats that these conditions raise substantial doubt about the company's ability to continue as a going concern. The only funding in the period was $117,084 of new 10% promissory notes, which pushed total notes payable to $389,388 against a working capital deficit of $829,189. No firm financing agreements are in place; the company plans to seek a private equity offering, which would mean further dilution for existing holders. Disclosure controls were again deemed not effective.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LMED was trading at $0.04 on OTC in the Technology sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $0.03 to $135.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.